SDS

Across TCGA pan-cancer cohorts, SDS mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SDS data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SDS mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SDS expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where SDS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.919	0.689	.010	12	view →
GBM	DFS	Quartile	All	0.358	0.190	.022	3	view →
PDAC	OS	Tertile	III,IV	0.852	0.274	.026	2	view →
LSCC	OS	Tertile	All	0.712	0.871	.033	2	view →
HNSC	DFS	Quartile	II,III,IV	0.919	1.000	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SDS–CCRCC (OS)

Open the CCRCC breakdown →